Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
17. Mai 2024 17:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
15. Mai 2024 16:05 ET
|
Athira Pharma, Inc.
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
Athira Pharma to Participate in Upcoming May Conferences
02. Mai 2024 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
15. April 2024 07:00 ET
|
Athira Pharma, Inc.
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer.
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
11. April 2024 07:00 ET
|
Athira Pharma, Inc.
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
03. April 2024 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal...
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
08. März 2024 07:00 ET
|
Athira Pharma, Inc.
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s & Parkinson’s Diseases at AD/PD™ 2024
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
22. Februar 2024 16:05 ET
|
Athira Pharma, Inc.
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
08. Februar 2024 16:02 ET
|
Athira Pharma, Inc.
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
08. Januar 2024 07:00 ET
|
Athira Pharma, Inc.
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update